according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 2024/09/28 772743-00020 Date of first issue: 2016/06/23 7.0

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mometasone / Posaconazole / Gentamicin / Polymyxin B For-

mulation

Manufacturer or supplier's details

MSD Company

Address No. 485 Jing Tai Road

Pu Tuo District - Shanghai - China 200331

Telephone +1-908-740-4000

Emergency telephone number: 86-571-87268110

E-mail address EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use Veterinary product Not applicable Restrictions on use

### 2. HAZARDS IDENTIFICATION

#### **Emergency Overview**

**Appearance** liquid

Colour No data available Odour No data available

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

**GHS Classification** 

Reproductive toxicity Category 1A

Specific target organ toxicity - : Category 2

repeated exposure

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

: Category 1

#### **GHS** label elements

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Hazard pictograms :





Signal word : Danger

Hazard statements : H360D May damage the unborn child.

H373 May cause damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

#### Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapours. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

#### Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

#### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Physical and chemical hazards

Not classified based on available information.

## **Health hazards**

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

#### **Environmental hazards**

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

## Other hazards which do not result in classification

None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 Date of first issue: 2016/06/23 7.0 2024/09/28 772743-00020

Chemical name	CAS-No.	Concentration (% w/w)	
Gentamicin	1403-66-3	>= 1 -< 2.5	
Posaconazole	171228-49-2	>= 0.25 -< 1	
Mometasone	83919-23-7	>= 0.25 -< 0.3	
3-Mercaptopropane-1,2-diol	96-27-5	>= 0.1 -< 0.25	

#### 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. : Flush eyes with water as a precaution. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water. May damage the unborn child.

Most important symptoms and effects, both acute and

delayed

May cause damage to organs through prolonged or repeated

exposure.

Protection of first-aiders First Aid responders should pay attention to self-protection.

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

#### 5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

## 7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

**Storage** 

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis		
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal		
	Further inform	Further information: OTO				
Posaconazole	171228-49-2	TWA	300 μg/m3 (OEB 2)	Internal		
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal		
	Further inform	Further information: Skin				
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal		

**Engineering measures** : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist,

handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Combined particulates and organic vapour type

Filter type : Combined particulates and organic vapour type Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : No data available

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 Date of first issue: 2016/06/23 2024/09/28 772743-00020 7.0

Evaporation rate No data available

Flammability (solid, gas) Not applicable

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure No data available

No data available Relative vapour density

Relative density No data available

Density No data available

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature No data available

Decomposition temperature No data available

Viscosity

Viscosity, kinematic No data available

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle characteristics

Particle size Not applicable

### 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Can react with strong oxidizing agents.

Possibility of hazardous reac-

tions

Conditions to avoid None known.

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Incompatible materials

Hazardous decomposition

products

: Oxidizing agents

No hazardous decomposition products are known.

#### 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

#### **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

#### **Components:**

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg

LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of:

administration)

LD50 (Rat): 67 - 96 mg/kg

Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Posaconazole:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 Date of first issue: 2016/06/23 2024/09/28 772743-00020 7.0

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of : LD50 (Rat): 300 mg/kg

administration)

Application Route: Subcutaneous Symptoms: Breathing difficulties

3-Mercaptopropane-1,2-diol:

Acute oral toxicity : LD50 (Rat): 648 mg/kg

Acute dermal toxicity : LD50 (Rabbit): 673 mg/kg

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Gentamicin:

**Species** Rabbit

Result Mild skin irritation

Posaconazole:

Species Rabbit

Result No skin irritation

Mometasone:

Species Rabbit

Result No skin irritation

3-Mercaptopropane-1,2-diol:

Species Rabbit Result Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

**Components:** 

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

Posaconazole:

Species : Rabbit

Result : Mild eye irritation

Mometasone:

Species : Rabbit

Result : No eye irritation

3-Mercaptopropane-1,2-diol:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Gentamicin:

Remarks : No data available

Posaconazole:

Test Type : Magnusson-Kligman-Test

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

3-Mercaptopropane-1,2-diol:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation

rate in humans

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

Posaconazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow

Application Route: Intravenous

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells

Result: negative

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: 7.0 2024/09/28 772743-00020

Date of last issue: 2024/07/06 Date of first issue: 2016/06/23

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### 3-Mercaptopropane-1,2-diol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### Gentamicin:

Carcinogenicity - Assess- : No data available

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

#### ment

#### Posaconazole:

Species : Rat
Application Route : oral (feed)
Exposure time : 2 Years
Result : positive

Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : positive

Remarks : The mechanism or mode of action is not relevant in humans.

#### Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

#### Reproductive toxicity

May damage the unborn child.

### **Components:**

### Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3.6 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-foetal toxicity

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

#### Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male

General Toxicity - Parent: NOAEL: 180 mg/kg body weight

Symptoms: No effects on mating performance

Result: negative

Test Type: Fertility/early embryonic development

Species: Rat, female

General Toxicity - Parent: NOAEL: 45 mg/kg body weight

Symptoms: No effects on mating performance

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat, female Application Route: Oral

Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rabbit, female

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

#### Mometasone:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Symptoms: Reduced embryonic survival, Reduced foetal

weight

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

#### 3-Mercaptopropane-1,2-diol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

nent

Test Type: Embryo-foetal development

Species: Rat

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Application Route: Ingestion Method: OECD Test Guideline 414

Result: negative

Remarks: Based on data from similar materials

#### STOT - single exposure

Not classified based on available information.

#### **Components:**

#### Mometasone:

Remarks : Based on available data, the classification criteria are not met.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

#### Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

#### Posaconazole:

Exposure routes : Ingestion

Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive

organs, Nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

#### Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

#### Components:

#### Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Symptoms : Vomiting, Salivation

Species: MonkeyLOAEL: 50 mg/kgApplication Route: SubcutaneousExposure time: 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

### Posaconazole:

Species : Rat, female
LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species : Dog
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 392 Days

Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal

cord, lymphoid tissue

Species : Monkey
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 1 Months

Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species : Dog

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

3 mg/kg LOAEL Application Route Oral Exposure time : 56 Weeks

: Adrenal gland, Bone marrow, Kidney, Nervous system, Target Organs

spleen, thymus gland, Testis, lymphoid tissue

**Species** Monkey LOAEL
Application Route
Exposure time
Target Organs 180 mg/kg : Oral : 12 Months

: Blood, Gastrointestinal tract, spleen Target Organs

Species : Monkey LOAEL : 8 mg/kg Application Route : Intravenous Exposure time : 1 Months

Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

Mometasone:

Species Rat

NOAEL : 0.005 mg/kg LOAEL : 0.3 mg/kg Application Route : Oral Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

**Species** Dog LOAEL 0.5 mg/kg Application Route Oral Exposure time 30 d

Target Organs Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

**Species** Rat

NOAEL 0.00013 mg/l

Application Route inhalation (dust/mist/fume)

Exposure time 90 d

Target Organs Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species Dog

0.0005 mg/l NOAEL

inhalation (dust/mist/fume) Application Route

Exposure time 90 d

Target Organs Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

3-Mercaptopropane-1,2-diol:

Species Rat

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

LOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 55 Days

Method : OECD Test Guideline 422

Remarks : Based on data from similar materials

#### **Aspiration toxicity**

Not classified based on available information.

#### **Components:**

#### Mometasone:

Not applicable

### Experience with human exposure

#### **Components:**

Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

Posaconazole:

Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver

effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia,

electrolyte imbalance

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

**Further information** 

**Components:** 

Mometasone:

Remarks : Dermal absorption possible

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 2024/09/28 772743-00020 Date of first issue: 2016/06/23 7.0

#### 12. ECOLOGICAL INFORMATION

#### **Ecotoxicity**

#### **Components:**

#### Gentamicin:

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

M-Factor (Chronic aquatic

: 1

100

toxicity)

Toxicity to microorganisms EC50: 288.7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Posaconazole:

LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Toxicity to fish

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.276 mg/l

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

aquatic invertebrates Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: EC50 (Pseudokirchneriella subcapitata (green algae)): >

0.509 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.244 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

: 1

Toxicity to microorganisms

: EC50 (Natural microorganism): > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

plants

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.00014

mg/

100

mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.34 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

Toxicity to microorganisms : E

EC50: > 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

3-Mercaptopropane-1,2-diol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 10 - 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 - 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Raphidocelis subcapitata (freshwater green alga)): >

10 - 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

EC10 (Raphidocelis subcapitata (freshwater green alga)): > 1

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (activated sludge): > 1 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

### Persistence and degradability

#### **Components:**

Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

Posaconazole:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 h

Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d

Method: OECD Test Guideline 111

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)

Method: OECD Test Guideline 111

3-Mercaptopropane-1,2-diol:

Biodegradability : Result: Readily biodegradable.

Remarks: Based on data from similar materials

**Bioaccumulative potential** 

**Components:** 

Gentamicin:

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Partition coefficient: n-

octanol/water

: log Pow: < -2

Posaconazole:

Bioaccumulation Species: Lepomis macrochirus (Bluegill sunfish)

> Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 4.15

Mometasone:

Bioaccumulation Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.68

3-Mercaptopropane-1,2-diol:

Partition coefficient: n-

octanol/water

: log Pow: -0.84

Method: OECD Test Guideline 117

Mobility in soil

**Components:** 

Posaconazole:

Distribution among environ-

mental compartments

: log Koc: 5.52

Mometasone:

Distribution among environ-

mental compartments

: log Koc: 4.02

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

**UNRTDG** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Gentamicin, Mometasone)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Gentamicin, Mometasone)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen- :

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

964

(Gentamicin, Mometasone)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **National Regulations**

GB 6944/12268

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Gentamicin, Mometasone)

Class : 9
Packing group : III
Labels : 9
Marine pollutant : no

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 15. REGULATORY INFORMATION

### **National regulatory information**

### Law on the Prevention and Control of Occupational Diseases

#### **Regulations on Safety Management of Hazardous Chemicals**

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of de-

termination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

#### Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

## Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

### **Regulation on the Administration of Precursor Chemicals**

Catalogue and Classification of Precursor Chemicals : Not listed

### Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

## The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 16. OTHER INFORMATION

Revision Date : 2024/09/28

according to GB/T 16483 and GB/T 17519



## Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version SDS Number: Date of last issue: 2024/07/06 Revision Date: Date of first issue: 2016/06/23 7.0 2024/09/28 772743-00020

#### **Further information**

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

according to GB/T 16483 and GB/T 17519



# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 7.0 2024/09/28 772743-00020 Date of first issue: 2016/06/23

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN